Skip to main content
B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity
Published Web Location
http://europepmc.org/articles/PMC4405474?pdf=renderNo data is associated with this publication.
Abstract
© 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.Natalizumab, which binds very late antigen-4 (VLA-4), is a potent therapy for multiple sclerosis (MS). Studies have focused primarily
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.